Skip to main content

Smith + Nephew Plc Value Stock - Dividend - Research Selection

Smith and nephew

ISIN: GB0009223206 , WKN: 502816

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Smith+Nephew takes centre court sponsoring players competing at Wimbledon; global Sports Medicine technology leader helping athletes get back in the game

2024-06-26
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will sponsor tennis players participating in The Championships, Wimbledon 2024 to spotlight its advanced Sports Medicine portfolio alongside some of the greatest athletes in the world. Smith+Nephew endeavours to help people live their ‘Life Unlimited’ by aiding in their recovery from injury and get them back to doing what they love. Click to play video - Smith+Nephew Proud Player Sponsor at The Championshi

June 2024 Insights Into UK Stocks Estimated To Be Undervalued

2024-06-24
As global markets exhibit caution and the FTSE 100 faces downward pressure, investors are keenly observing economic indicators and geopolitical events that could influence market dynamics. In such a climate, identifying undervalued stocks in the UK market requires a nuanced understanding of both macroeconomic factors and individual company fundamentals.

Smith & Nephew's (SNN) CORIOGRAPH to Aid Arthroplasty Procedure

2024-06-14
Smith & Nephew (SNN) announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, exclusively for use with the CORI Surgical System.

Smith+Nephew personalizes robotic-assisted surgery for patients and surgeons with launch of CORIOGRAPH™ Pre-Operative Planning and Modeling Services exclusively for the CORI™ Surgical System

2024-06-12
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, providing an unparalleled, personalized solution for surgeons and patients across partial and total knee arthroplasty procedures. It is exclusively for use with the CORI Surgical System - the only orthopaedic robotic-assisted system to offer either intraoperative image-free or image-based registration, enabling the surgeon to choos

Smith & Nephew: Work To Be Done But Still Long-Term Potential

2024-06-11
Smith & Nephew showed decent top line growth with a 6.4% increase in revenue last year. Read more to see why SNN stock is a Buy.

Harris Associates International Equity Strategy Q1 2024 Commentary

2024-05-24
The portfolio’s return was 0.20% (net) for the reporting period. This compares to the MSCI World ex USA Index that returned 5.59% for the same period.

FMI Funds Q1 2024 Shareholder Letter

2024-05-17
2023's momentum carried over into Q1 2024, with growth stocks leading the charge (once again) across market caps and geographies. Click here to read more.

An Intrinsic Calculation For Smith & Nephew plc (LON:SN.) Suggests It's 34% Undervalued

2024-05-08
Key Insights Smith & Nephew's estimated fair value is UK£15.04 based on 2 Stage Free Cash Flow to Equity Current share...

Smith & Nephew plc (SNN) Q1 2024 Sales/Trading Statement Call Transcript

2024-05-01
Smith & Nephew plc (NYSE:NYSE:SNN) Q1 2024 Sales/Trading Statement Conference Call May 1, 2024 3:30 AM ETCompany ParticipantsDeepak Nath - Chief...

Q1 2024 Sales/ Trading Statement Call

2024-05-01
The following slide deck was published by Smith & Nephew plc in conjunction with this event.